NCT05270668: An ongoing trial by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
This trial is ongoing. It must report results 1 year, 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05270668 |
|---|---|
| Title | A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7240/PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 29, 2022 |
| Completion date | April 30, 2026 |
| Required reporting date | April 30, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |